

Product Update:

saxagliptin plus metformin, 2.5mg / 850mg and 2.5mg / 1000mg film-coated tablets (Komboglyze[®]) (No: 929/13)

Bristol-Myers Squibb / AstraZeneca

06 December 2013

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

saxagliptin plus metformin (Komboglyze[®]) is accepted for use within NHS Scotland.

Indication under review: in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus when the maximally tolerated dose of both metformin and the sulphonylurea does not provide adequate glycaemic control.

For patients in whom triple combination therapy with metformin, a sulphonylurea and saxagliptin is appropriate, saxagliptin/metformin has the potential to reduce the pill burden at a lower cost.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 15 October 2013.

**Vice Chairman,
Scottish Medicines Consortium**